A&O advises Ipsen in relation to the sale of its consumer healthcare business to Mayoly Spindler
Related people
Press contacts
For media enquiries relating to this topic, please contact:
15 February 2022
Allen & Overy Paris has advised Ipsen on its entry into exclusive negotiations with the pharmaceutical laboratory Mayoly Spindler in relation to the divestment of its consumer healthcare (CHC) business, which includes the drugs Smecta®, Forlax®, Tanakan®, Fortrans® and various production sites.
The combination of Ipsen’s and Mayoly Spindler’s respective CHC businesses will create a global consumer healthcare platform with a critical size and the capacity to support its growth. Capza and Caravelle, two financial investors, are supporting Mayoly Spindler and will provide part of the financing required to complete this transaction, by acquiring a minority stake in the new entity.
The transaction will be submitted to the relevant employee representative bodies of Ipsen. The closing of the transaction is expected before the end of the third quarter of 2022 upon completion of regulatory and antitrust filings and customary conditions precedent.
The Allen & Overy team is led by Marc Castagnède (Partner) and Romy Richter (Partner) with Frédéric Moreau (Partner), with support from Pauline Régnier (Associate) and Antoine Messent (Associate).
The team also included Olivier Picquerey (Partner), Susan Ekrami (Counsel) and Hovig Cancioglu (Associate) on employment law aspects, Florence Ninane (Partner) and Noémie Bomble (Associate) on antitrust aspects, Laurie-Anne Ancenys (Counsel ) and Juliette Olliveaud (Associate) on IT aspects and transitional services, Luc Lamblin (Counsel) on aspects related to the control of foreign investments, Guillaume Valois (Partner) and Charles del Valle (Counsel) on tax aspects, Arthur Sauzay (Counsel) and Marie Coussi (Associate) on public and environmental law aspects, Marianne Delassaussé (Senior Consultant) on intellectual property aspects.